Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462618 | 0.98 | TRPV1 (0.68) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16658696 | 0.98 | TRPV1 (0.68) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16658697 | 0.98 | TRPV1 (0.68) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16658733 | 0.98 | TRPV1 (0.68) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16658695 | 0.98 | TRPV1 (0.68) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL16658698 | 0.98 | TRPV1 (0.68) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL422827 | 0.94 | L3MBTL1 (0.68) | HPGDKMT2ASMN1; SMN2L3MBTL1CYP2D6 | |
| SCHEMBL7858 | 0.86 | KDM4E (0.69) | HPGDKMT2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL28286779 | 0.86 | L3MBTL1 (0.58) | HPGDKMT2ASMN1; SMN2L3MBTL1CYP2D6 | |
| SCHEMBL2019835 | 0.85 | TRPV1 (0.69) | TRPV1HPGDKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730141-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2006-12-13 | — | — | EP | claimed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2005092860-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | claimed |
| WO-2022272106-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-115466196-A | Preparation method of atorvastatin calcium intermediate | 宿迁阿尔法科技有限公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-112851538-B | Method for promoting acylation of amine or alcohol by carbon dioxide | 中国科学院兰州化学物理研究所 | 2022-05-20 | — | — | CN | disclosed |
| CN-113913416-B | Preparation process of alcaligenes faecalis penicillin G acylase | 巢湖学院 | 2022-03-22 | — | — | CN | disclosed |
| CN-113913416-A | Preparation process of alcaligenes faecalis penicillin G acylase | 巢湖学院 | 2022-01-11 | — | — | CN | disclosed |
| CN-112851538-A | Method for promoting acylation of amine or alcohol by carbon dioxide | 中国科学院兰州化学物理研究所 | 2021-05-28 | — | — | CN | disclosed |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| EP-1688420-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2006-08-09 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2005092841-A1 | COMPOUNDS HAVING BETA-AGONIST ACTIVITY | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| EP-0751132-B1 | Pyridazinone derivatives and processes for preparing the same | TANABE SEIYAKU CO (JP) | 2000-08-30 | — | — | EP | disclosed |
| CN-1043993-C | Nonel naphthyridine derivatives and medical composition thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1999-07-07 | — | — | CN | disclosed |
| US-5808065-A | AMIDATION OF THE CORRESPONDING AMINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5698554-A | PREVENTING AND TREATING NEPHRITIS, ENDOTOXIC SHOCK | TANABE SEIYAKU CO., LTD. (JP) | 1997-12-16 | — | — | US | disclosed |
| CN-1156455-A | Nonel naphthyridine derivatives and medical composition thereof | YAMANOUCHI PHARMACUEITCAL CO L (JP) | 1997-08-06 | — | — | CN | disclosed |
| EP-0751132-A1 | Pyridazinone derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | TRPV1 2001/4885HPGD 1292/4885KMT2A 2063/4885 |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | TRPV1 1319/4885HPGD 951/4885KMT2A 155/4885 |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | TRPV1 1319/4885HPGD 951/4885KMT2A 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.